Gleamer is a French med-tech company that builds artificial-intelligence tools to augment radiologists’ workflows. Its flagship platform, Gleamer Copilot, uses computer vision models to detect and quantify abnormalities on imaging studies. The company’s next product line, “OncoView,” will apply the same AI technology to oncology CT scans, initially targeting lung and bone metastases and later expanding to broader cancer imaging needs. Gleamer plans to invest €18 million over the next five years to develop a full suite of applications for lesion detection, measurement, and treatment-response monitoring. The project is being executed in partnership with leading French healthcare institutions and industrial collaborators, and is supported by a dedicated R&D team specializing in AI, data science, and clinical research. A €4.5 million government co-funding award under France’s “Digital Health” initiative will partially finance the effort, underscoring national recognition of the company’s technology and market leadership. Although operating metrics such as revenue or user count were not disclosed, management positions the company as a global leader in AI for medical imaging.

Total raised

$44M

Funding rounds

3

Latest round

Equity

Latest activity

Dec 2024